Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus

Journal of Viral Hepatitis

Volumn 13, Issue 12, 2006, Pages 799-810

  Backus, L I ^a   Boothroyd, D B ^a   Phillips, B R ^a   Mole, L A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hepatitis C virus; Hepatitis C virus treatment; HIV AIDS; HIV HCV coinfection; Race

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CREATININE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG USE; FEMALE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; SCREENING; VETERAN; VIRUS LOAD;

COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 33751001792     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00751.x     Document Type: Article

References (26)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8): 556-562.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34(6): 831-837.
3. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32(3): 492-497.
4. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. Aids 2004; 18(15): 2039-2045.
5. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33(3): 365-372.
6. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33(2): 240-247.
7. Quintana M, Del Amo J, Barrasa A et al. Progression of HIV infection and mortality by hepatitis C infection in patients with haemophilia over 20 years. Haemophilia 2003; 9(5): 605-612.
8. Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17(12): 1803-1809.
9. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292(23): 2839-2848.
10. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351(5): 451-459.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351(5): 438-450.
12. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids 2004; 18(13): F27-F36.
13. Philips BR, Mole LA, Backus LI, Halloran JP, Chang SW. Caring for Veterans with HIV Disease. Washington DC: Department of Veterans Affairs, 2003.
14. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C co-infection in vulnerable populations. AIDS 2005; 19 (Suppl. 3): 513-519.
15. Wright TL, Yee H. VA treatment recommendations for patients with chronic hepatitis C. Fed Practitioner 2003; 20 (Suppl. 5): 1-33.
16. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office. Am J Gastroenterol 2005; 100: 1-17.
17. Backus L, Mole L, Chang S, Deyton L. The immunology case registry. J Clin Epidemiol 2001; 54 (Suppl. 1): S12-S15.
18. Szeto HC, Coleman RK, Gholami P, Hoffman BB, Goldstein MK. Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. Am J Manag Care 2002; 8(1): 37-43.
19. Kashner TM. Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs. Med Care 1998; 36(9): 1324-1336.
20. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346-355.
21. Perez-Olmeda M, Nunez M, Romero M et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. Aids 2003; 17(7): 1023-1028.
22. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents - 7 April 2005. Available at: http://aidsinfo.nih.gov/ guidelines/default_db2.asp?id=50 (accessed 30 September 2005).
23. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30(3): 787-793.
24. Kinzie JL, Naylor PH, Nathani MG et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001; 8(4): 264-269.
25. De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002; 49(45): 788-792.
26. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350(22): 2265-2271.